S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
What to Expect from the Markets in a Recession
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
What to Expect from the Markets in a Recession
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
What to Expect from the Markets in a Recession
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
What to Expect from the Markets in a Recession
NASDAQ:APTX

Aptinyx - APTX Stock Forecast, Price & News

$0.51
+0.02 (+4.87%)
(As of 08/5/2022 08:48 PM ET)
Add
Compare
Today's Range
$0.51
$0.55
50-Day Range
$0.38
$0.72
52-Week Range
$0.36
$3.76
Volume
242,700 shs
Average Volume
332,109 shs
Market Capitalization
$34.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Aptinyx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
774.1% Upside
$4.50 Price Target
Short Interest
Healthy
2.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Aptinyx in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.99) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

350th out of 1,283 stocks

Pharmaceutical Preparations Industry

149th out of 615 stocks

APTX stock logo

About Aptinyx (NASDAQ:APTX) Stock

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on APTX shares. SVB Leerink cut their price objective on shares of Aptinyx from $4.00 to $3.00 and set an "outperform" rating on the stock in a report on Friday. HC Wainwright reduced their price target on Aptinyx from $8.00 to $2.00 and set a "buy" rating for the company in a report on Thursday, April 14th. Finally, Piper Sandler lowered their price target on Aptinyx from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, May 18th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $4.50.

Aptinyx Stock Performance

Shares of NASDAQ:APTX traded up $0.02 during trading hours on Friday, hitting $0.51. The stock had a trading volume of 242,733 shares, compared to its average volume of 149,757. Aptinyx has a 1-year low of $0.36 and a 1-year high of $3.76. The company has a debt-to-equity ratio of 0.31, a quick ratio of 22.49 and a current ratio of 22.49. The firm has a market capitalization of $34.86 million, a price-to-earnings ratio of -0.45 and a beta of 1.24. The stock's fifty day simple moving average is $0.53 and its 200 day simple moving average is $1.59.

Aptinyx (NASDAQ:APTX - Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02. During the same quarter last year, the business posted ($0.22) earnings per share. Sell-side analysts anticipate that Aptinyx will post -0.99 earnings per share for the current fiscal year.

Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

APTX Stock News Headlines

Aptinyx (APTX) to Release Quarterly Earnings on Thursday
Expert Ratings for Aptinyx
See More Headlines
Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

APTX Company Calendar

Last Earnings
5/12/2022
Today
8/07/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTX
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+774.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-74,890,000.00
Pretax Margin
-7,488.60%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$1.40 per share

Miscellaneous

Free Float
61,026,000
Market Cap
$34.86 million
Optionable
Not Optionable
Beta
1.24














APTX Stock - Frequently Asked Questions

Should I buy or sell Aptinyx stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aptinyx stock.
View analyst ratings for Aptinyx
or view top-rated stocks.

What is Aptinyx's stock price forecast for 2022?

6 brokers have issued 1-year price targets for Aptinyx's shares. Their APTX stock forecasts range from $2.00 to $6.00. On average, they predict Aptinyx's stock price to reach $4.50 in the next year. This suggests a possible upside of 774.1% from the stock's current price.
View analysts' price targets for Aptinyx
or view top-rated stocks among Wall Street analysts.

How has Aptinyx's stock price performed in 2022?

Aptinyx's stock was trading at $2.67 at the beginning of the year. Since then, APTX stock has decreased by 80.7% and is now trading at $0.5148.
View the best growth stocks for 2022 here
.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our earnings forecast for Aptinyx
.

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) announced its earnings results on Thursday, August, 4th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03. During the same period in the prior year, the company earned ($0.29) earnings per share.

What other stocks do shareholders of Aptinyx own?

When did Aptinyx IPO?

(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.17%) and Silverarc Capital Management LLC (0.00%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Bain Capital Life Sciences Inv, Joan W Miller, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Robert J Hombach.
View institutional ownership trends for Aptinyx
.

How do I buy shares of Aptinyx?

Shares of APTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $0.51.

How much money does Aptinyx make?

Aptinyx (NASDAQ:APTX) has a market capitalization of $34.86 million and generates $1 million in revenue each year. The company earns $-74,890,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How many employees does Aptinyx have?

Aptinyx employs 40 workers across the globe.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The official website for Aptinyx is www.aptinyx.com. The company can be reached via phone at (847) 871-0377 or via email at investors@aptinyx.com.

This page (NASDAQ:APTX) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.